Delivery Order SPE2DB20D3103-SPE2DB25FQ0Q0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,301.12 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/ml infusion bottles (150 ml units). This firm fixed-price delivery order, awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Visipaque 320 mg/ml infusion bottles (150 ml units) with a ceiling value of $4,126.40. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. The award was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,038.55 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/mL infusion bottles (150 mL units). This firm fixed-price delivery order, awarded on August 15, 2025, represents a non-competitive set-aside procurement and will be fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. Visipaque is a contrast medium used in...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $16,296.38 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/ml in 100ml bottles. This competitively awarded, firm fixed price contract was executed on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $2,002.68, for Visipaque 320 mg/ml in a 100 ml bottle. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, issued on July 29, 2025. The award is non-competitive set-aside and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $32,271.62 by the Medical Supply Chain, a component of the Department of Defense, for the supply of Visipaque 320 mg/ml in 100 ml bottles. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and represents a non-set-aside procurement. The contract was executed on August 13, 2025, with performance to take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $3,004.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/mL, a contrast agent used in medical imaging procedures. This award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a child order under a larger contract vehicle. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award, reflecting...
- The Defense Logistics Agency awarded a $5,006.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Visipaque 320 mg/mL in 100 mL bottles. The contract, which represents a non-set-aside, competitively awarded delivery order, is scheduled for ultimate completion by August 14, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Visipaque is a contrast media used in diagnostic imaging...
- This federal contract award, valued at $2,531.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of Visipaque 320 mg/ml infusion bottles, a pharmaceutical product used for medical imaging. The contract has an ultimate completion date of October 17, 2024 and is a firm fixed-price arrangement. While the original solicitation was not provided, the...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $1,687.64 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide VISIPAQUE 320 MG/ML INFUS BTL 150ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ0Q0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,063.20 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/ml infusion bottles (150 ml) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-competitive set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables AmerisourceBergen to supply medications and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor serving military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio encompasses a wide range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for Visipaque, a contrast medium used in diagnostic imaging procedures, exemplifies the company's role in fulfilling specialized medical supply requirements for defense healthcare operations. The competitively-awarded parent indefinite delivery contract reflects AmerisourceBergen's capability to meet federal procurement standards and its significance as a primary supplier within the DLA's pharmaceutical procurement strategy.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/28/25 |